Benzinga | Feb 25, 2021 11:15AM EST

Atossa Therapeutics' COVID-19 Nasal Spray Safe In Early-Stage Study

* Atossa Therapeutics Inc (NASDAQ: ATOS) announces final results from its Phase 1 study evaluating AT-301 administered by nasal spray. AT-301 is being developed for at-home use for patients recently diagnosed with COVID-19.

* The treatment was considered to be safe and well-tolerated at two different dose levels over 14 days.

* The final analysis indicates that there were no serious adverse events, no discontinuations, no bronchospasm.

* Only one of the 32 subjects in the study experienced moderate adverse events, and all other adverse events were considered mild.

* An additional pre-clinical study is expected to start this quarter.

* Price Action: ATOS surged 8.6% at $3.02 on the last check Thursday.